Glomus Tumor (Head & Neck Paraganglioma), explained simply

Watch: the CureRays® explainer series

Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.

What is glomus tumor (head & neck paraganglioma)?

A glomus tumor — more precisely a head and neck paraganglioma — is a tumor that grows from small clusters of specialized cells (paraganglia) that normally sit alongside blood vessels and nerves and help sense and regulate the body. In the head and neck these tumors form in a few characteristic spots: at the carotid artery in the neck (carotid body tumor), in the bone behind the ear near the hearing and balance structures (glomus tympanicum and glomus jugulare), and along the vagus nerve (glomus vagale). The great majority are benign, meaning they are not cancer and rarely spread, but they are locally important because they are highly vascular (full of blood vessels) and grow in crowded areas right next to major arteries, the hearing and facial nerves, and the nerves that control swallowing and the voice. As they slowly enlarge they can cause a pulsing sound in the ear, hearing loss, dizziness, a neck mass, hoarseness, or difficulty swallowing. A small minority release hormones (catecholamines) that can raise blood pressure and heart rate, which is checked for before any procedure because it changes how the tumor is handled. Two features shape modern care. First, because these tumors grow slowly and sit among delicate nerves and vessels, the goal is durable control with the least harm — and focused radiation has become a leading way to achieve that, often controlling the tumor without the nerve injury or major bleeding risk that surgery can carry. Second, a substantial share of head and neck paragangliomas are linked to inherited gene changes (most commonly in the SDHx genes), so finding one — especially several, or one at a young age — should prompt genetic counseling and screening for additional tumors elsewhere in the body.

The main types

Doctors group glomus tumor (head & neck paraganglioma) by where it starts and how it behaves:

Staging, in plain terms

Most head and neck paragangliomas are benign, so they are not given a cancer stage like a malignant tumor. Instead, surgeons and radiation oncologists describe them using practical classifications based on size and how much they encase nearby blood vessels and nerves. Carotid body tumors, for example, are often graded by how completely they wrap around the carotid artery (the Shamblin classification), which predicts how difficult and risky removal would be; skull-base glomus jugulare tumors are described by how far they extend into bone and around the lower cranial nerves (such as the Fisch classification). These descriptions matter because they guide the central decision: whether to remove the tumor, irradiate it, or simply watch it. Two further assessments are routine. Doctors check whether the tumor releases hormones, because a secreting paraganglioma must be controlled with medication first to keep blood pressure stable during any procedure. And because many of these tumors are hereditary, genetic testing — particularly for the SDHx genes — is offered, since an inherited cause raises the chance of additional paragangliomas elsewhere and warrants whole-body screening. A small number of paragangliomas are malignant, defined by spread to lymph nodes or distant sites rather than by local appearance; those are staged and treated more aggressively. For the typical benign tumor, though, the framework is location, size, nerve/vessel involvement, hormone status, and genetics rather than a stage number.

The standard of care

Glomus Tumor (Head & Neck Paraganglioma) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:

How radiation treatment works

Radiation therapy controls glomus tumors by delivering focused energy that damages the DNA of the tumor cells and, over time, the rich network of blood vessels that feeds them, so the tumor stops growing. Because these tumors are usually benign and slow-growing, the aim of radiation is local control — stabilizing a tumor in its crowded location so it no longer threatens nearby nerves and vessels — rather than eradicating a spreading cancer. This is exactly why radiation has become so prominent for head and neck paragangliomas, particularly glomus jugulare tumors at the base of the skull. There, surgery sits among the lower cranial nerves that control swallowing, the voice, and the tongue, as well as the hearing and facial nerves, so an operation can carry a meaningful risk of lasting nerve injury and significant bleeding from the tumor's vascularity. Stereotactic radiosurgery offers an alternative that controls the great majority of these tumors while leaving those nerves intact: a high, sharply focused dose is delivered in one or a few sessions, conforming tightly to the tumor and falling off quickly at its edges to protect the surrounding structures. For larger tumors or those abutting especially sensitive areas, the dose can instead be divided over several treatments to further spare healthy tissue. The benefit develops gradually, over months to a couple of years, as the tumor's blood vessels close down and growth halts or the tumor slowly shrinks; lasting tumor control is achieved in roughly nine out of ten patients in long-term series, with low rates of new nerve problems. Radiation can also be used after surgery when a tumor cannot be completely removed. In the rare event that a paraganglioma is malignant and has spread, a different form of radiation — targeted radionuclide therapy such as MIBG or PRRT — can deliver radiation from inside the body to tumor deposits wherever they are. Embolization, which blocks the tumor's blood supply, is sometimes used before surgery, but is generally not needed when radiation is the chosen treatment. Overall, focused radiation gives these benign but awkwardly located tumors a durable, function-preserving form of control.

The main ways radiation is delivered for glomus tumor (head & neck paraganglioma):

Latest studies shaping care

Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:

Common questions

Is a glomus tumor cancer? Almost always, no. The great majority of head and neck glomus tumors (paragangliomas) are benign — they grow slowly and rarely spread. They matter because of their location, wrapped around major blood vessels and the nerves that control hearing, the face, the voice, and swallowing. Only a small minority are malignant, defined by spread to lymph nodes or distant sites, and those are treated more aggressively.

Why might radiation be chosen over surgery? Many of these tumors sit at the skull base among delicate nerves, where surgery can risk lasting injury to swallowing, the voice, the face, or hearing, plus significant bleeding because the tumors are so vascular. Focused radiation (stereotactic radiosurgery) controls the tumor in about nine out of ten cases while preserving those nerves, so it is often preferred for glomus jugulare and other hard-to-reach tumors. Accessible tumors may still be best removed surgically.

Should my family be tested? Possibly. A significant share of head and neck paragangliomas are linked to inherited gene changes, most often in the SDHx genes — especially when there is more than one tumor, a young age at diagnosis, or a family history. Genetic counseling can clarify the risk, guide screening for additional tumors elsewhere in the body, and determine whether relatives should be tested.

Talk to a CureRays radiation oncologist Back to all guides